莫西沙星治疗社区获得性肺炎的疗效观察  

Observation of clinical effect of moxifloxacin for the treatment of community acquired pneumonia

作　　者：郭小燕[1] 潘江[2] 张瑛[1] 周芸[1] 黄玲[1] 

机构地区：[1]长治医学院护理学院,山西长治046000 [2]长治医学院附属和平医院,山西长治046000

出　　处：《中华医院感染学杂志》2014年第11期2683-2684,2687,共3页Chinese Journal of Nosocomiology

基　　金：山西省高等学校社会科学研究基金资助项目(20122202)

摘　　要：目的观察莫西沙星治疗社区获得性肺炎的临床疗效及安全性。方法将130例老年社区获得性肺炎患者随机分成治疗组和对照组,每组各65例,治疗组患者给予莫西沙星注射液静脉滴注,对照组患者给予左氧氟沙星静脉滴注,治疗12周后比较两组患者的临床疗效。结果治疗组60例有效,总有效率为92.3%,对照组44例有效,总有效率67.7%,治疗组总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗组的细菌清除率为84.6%,显著高于对照组的55.4%,差异有统计学意义(P<0.05);治疗组有4例出现轻度恶心,药物不良反应的发生率为6.2%,对照组2例出现轻度恶心、4例出现皮疹,药物不良反应的发生率为9.2%,治疗组药物不良反应的发生率低于对照组,但差异无统计学意义。结论莫西沙星组的治疗有效率和细菌清除率明显优于左氧氟沙星,且更安全有效;莫西沙星治疗社区获得性肺炎在临床治疗中是优选方案,值得临床推广应用。OBJECTIVE To observe the clinical efficacy and safety of moxiftoxacin in the treatment of community acquired pneumonia. METHODS A total of 130 cases with community acquired pneumonia enrolled in the study were randomly divided into treatment group （65 cases） and control group （65 cases）. Treatment group was treated with intravenous injection of moxifloxacin, and the control group was treated with intravenous injection of levofloxacin. The clinical efficacy of treatment was observed after treatment for 12 weeks. RESULTS A total of 60 cases were effective in the treatment group, with the overall clinical effective rate of 92. 3%, 44 cases were effective in the control group, with the overall clinical effective rate of 67.7%, and the difference between the two groups was statistically significant （P〈0.05）. The bacterial clearance rate of the treatment group was 84.6%, which was significantly higher than the control group （55.4%） （P〈0.05）. A total of 4 cases had mild nausea in the treatment group, and the incidence of adverse drug reactions of the treatment group was 6.2%, and 2 cases had mild nausea in the control group, 4 cases had skin rash, and the incidence of adverse drug reactions of the control group was 9. 2%. Occurrence of the adverse reaction of the treatment group was less than that of the control group, but the differences was not significant. CONCLUSIONS The overall clinical effective rate and the bacterial clearance rate of moxifloxaein group is superior to that of levofloxcine group, and it is more effective and safer for the treatment of patients with community acquired pneumonia. Moxifloxacin is the preferred plan in the clinical treatment of CAP. It is worth to be promoted in the clinical application.

关 键 词：老年 社区获得性肺炎 莫西沙星 左氧氟沙星 耐药 

分 类 号：R978.1[医药卫生—药品]